Ciphergen, Orchid BioSciences, BioMrieux, Cepheid, Lynx Therapeutics, Exiqon, ViaLogy, Myriad genetics, Abbott Laboratory, Pfizer, Perlegen | GenomeWeb

Ciphergen Said Q4 Revenue will be $3M Below Original Forecast

Ciphergen Biosystems’ fourth-quarter revenues will fall short of prior forecasts by approximately $3 million, the company said last week.

Total receipts for the period ended Dec. 31 will be in the range of $15 million to $15.5 million, not $19 million as previously expected, Ciphergen said. Revenue for the year is slated to come in at $58.5 million, a 50 percent year-over-year increase.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.